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A human induced pluripotent stem cell (hiPSC) line was previously
generated from a skin biopsy obtained from a 58-year-old male
Alzheimer's disease (AD) patient carrying a heterozygous point muta-
tion (c.449CNT) in exon 6 of the presenilin 1 (PSEN1) gene
(Tubsuwan et al., 2016). The single base pair mutation results in the
substitution of leucine (L) to proline (P) at position 150 of the amino
acid sequence (i.e., L150P). To generate a patient-speciﬁc and integra-
tion-free hiPSC line, episomal plasmids carrying gene sequences for
hOCT4, hSOX2, hKLF4, hL-MYC, hLIN28 and a short hairpin against TP53
(Okita et al., 2011) were used to reprogram patient's ﬁbroblasts into
hiPSCs (Tubsuwan et al., 2016). Here, we used this hiPSC line to further
generate an isogenic control line, L150P-GC-hiPSC, by employing the
CRISPR/Cas9 system (Ran et al., 2013) to correct the c.449CNTmutation.
Genomic sequences manipulated for gene editing are shown in Fig. 1A.
Correction of the point mutation (C N T) was validated by sequencing
(Fig. 1B). The L150P–GC-hiPSC was characterized to be karyotype nor-
malwith 46, XY (Fig. 1C) and expressed commonpluripotencymarkers:Freude KK, Holst B. Generation of induced
pluripotent stem cells (iPSCs) from an
Alzheimer's disease patient carrying a L150P
mutation in PSEN-1. Stem Cell Research. 2016;
16: 110–112.
Information in public databases N/A
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1A. CRISPR/Cas9 and ssODN used to correct for the point mutation in L150P-hiPSC. (A) Genomic sequence of PSEN1 exon 6 containing the point mutation is highlighted in red. The
sgRNA recognizes the 23 bp genomic sequence as delineated by the blue box and the triangle indicates the CRISPR cutting site. Forward and reverse primer sequences highlighted in
yellow were used for colony screening and sequencing. (B) The ssODN sequence serves as a template for the correction of point mutation from C to T.
467A. Poon et al. / Stem Cell Research 17 (2016) 466–469OCT4, NANOG, SSEA3, SSEA4, TRA-1-60 and TRA-1-81 (Fig. 1D).
This study was approved by the “De Videnskabsetiske Komiteer for Re-
gion Hovedstaden” (protocol number H-4-2011-157), Copenhagen,
Denmark, and informed consent was obtained from the patient and
his family. As part of privacy protection, no personal information of
the patient is provided here.
Materials and methods
CRISPR design
The isogenic gene-corrected control L150P-GC-hiPSC was generated
using the CRISPR/Cas9 technology in combination with single-stranded
oligonucleotides (ssODNs) to guide the site-speciﬁc correction of the
L150P mutation.
We adopted the protocol published by Ran et al. (2013) and de-
signed the single-guide RNAs (sgRNAs) using the Zhang Lab software
(http://crispr.mit.edu/). The sgRNAs was cloned into Cas9 expressingFig. 1B. Sequencing of PSEN1 to conﬁrm CRISPR/Cas9 and ssODN-mediated gene correction. (A)
point mutation where the mutant allele with “C” nucleotide (blue) is detected in addition to th
indicating the successful replacement of the “C”with a “T”.plasmids (pSpCas9(BB)-2 A–Puro (PX459) V2.0; addgene ID 62988).
The ssODN contained the T (i.e., wild-type) nucleotide to replace the
mutant “C” at the site ofmutation. It also contained two additional silent
mutations, one up- and one down-stream of the mutation site for posi-
tive colony selection with the appropriate restriction enzyme.
Nucleofection
L150P-hiPSCs grown on matrigel-coated (Corning Bioscience)
dishes with E8 medium (Gibco) were detached with Accutase (Gibco).
2 × 106 single cells were transfected with 10 μg of CRISPR/Cas9 plasmid
and 100 pmol of ssODN using the Amaxa 4D Nucleofector (program
CA137, Lonza) and P3 Primary Cell Kit (Lonza) according to the
manufacturer's instructions. Transfected hiPSCs were cultured on
matrigel-coated dish with E8 medium supplemented with 1 mM
ROCK inhibitor (Sigma). Transfected hiPSCs were then subjected to pu-
romycin selection 4 h after nucleofection and cultured in the presence of
puromycin for the next 5 days. Puromycin-resistant colonies werePatient PSEN1 sequence before gene correction. The black vertical line indicates the site of
e normal allele with the “T” nucleotide (red). (B) Sequencing result after gene correction
Fig. 1C. Representative normal karyotype of L150-GC-hiPSC with 46, XY.
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in the E8 medium.Genotyping and restriction assays
DNA for genotyping was extracted using the prepGem™ Kit
(ZyGEM, PTI0500) (Qiagen). PCR with primers spanning the site of mu-
tation was performed using TEMPase Hot Start DNA Polymerase
(Ampliqon) according to the manufacturer's instructions. PCR products
were puriﬁed and digested with BseNI (Thermo Scientiﬁc) at 65 °C for
20 min. This enzyme only cuts DNA from hiPSC colonies with the
corrected allele from the ssODN containing the T nucleotide at the mu-
tation site.Sanger sequencing
Positive clones were sequenced using the ABI PRISM 310 Genetic
Analyzer for the presence of the corrected nucleotide at the site of mu-
tation. Sequences were also inspected for frameshifts and mutations
that might arise from the CRISPR-mediated gene editing.Immunoﬂuorescence staining
L150-GC-hiPSCs were ﬁxed with 4% paraformaldehyde in PBS for
15 min, blocked, and incubated with primary antibodies listed in Table
1 overnight at 4 °C. The next day, cells were incubated with the appro-
priate secondary antibodies and counterstained with DAPI. Images
were acquired using the Leica DMRB-ﬂuorescence microscope (Leica
Microsystems, Wetzlar, Germany).Karyotyping
L150-GC-hiPSCs were karyotyped using standard cytogenetic proce-
dures. In brief, cells were treated for 45 min with KaryoMAX colcemid
(Life Technologies), harvested in fresh ﬁxative consisted of 25% acetic
acid and 75%methanol, and subjected for G-band karyotyping at the In-
stitute of Medical Genetics and Applied Genomics (University of
Tübingen, Tübingen, Germany).
Veriﬁcation and Authentication.
L150-GC-hiPSC karyotyping was performed by the Institute of Med-
ical Genetics and Applied Genomics, University of Tübingen (Tübingen,
Germany). A minimum of 20 metaphases were analyzed. The results
showed a normal 46, XY karyotype without any detectable abnormali-
ties (Fig. 1C). The identity and purity of this line was conﬁrmed by se-
quencing of PSEN1 (Fig. 1B) and expression of several pluripotency
genes (Fig. 1D).
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Table 1
Primary antibodies used for immunocytochemistry.
Antibody and host species Dilution Company and catalog number
rabbit anti-NANOG 1:50 Peprotech, 500-P236
goat anti-OCT4 1:100 Santa Cruz, sc-8628
rat anti-SSEA3 1:100 Biolegend, 330302
mouse anti-SSEA4 1:100 Biolegend, 330402
mouse anti-Tra-1-60 1:200 Biolegend, 330602
mouse anti-Tra-1-81 1:200 Biolegend, 330702
Fig. 1D. Immunoﬂuorescence staining of L150P-GC-iPSCs with pluripotency markers: OCT4, NANOG, SSEA3, SSEA4, TRA1–60 and TRA1–81. Scale bars correspond to 100 μm.
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